A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to HER2-Positive Gastric Cancer
Related studies linked through entity extraction aliases.